Recent Research Funding

We receive funding from a variety of sources that recognize the value of our high-impact research.

  • A Ribozyme Rescue Strategy for Dry Age-Related Macular Degeneration. John Sullivan (Principal Investigator). VA Central Office. $330,000. 1/1/2025-12/1/2027.
  • Epigenetic Architecture of the RPE and Choroid: Identification of Therapeutic Targets For AMD. Margaret DeAngelis (Principal Investigator). Macular Degeneration Foundation, Inc. $500,000. 5/1/2020-7/1/2025.
  • Ancestry Network for the human cell atlas in the eye. Margaret DeAngelis (Co-Principal Investigator). Chan-Zuckerberg Initiative. $536,859. 2/1/2022-1/1/2025.
  • Pediatric network for the human cell atlas in the eye. Margaret DeAngelis (Co-Principal Investigator). Chan-Zuckerberg. $517,500. 2/1/2022-1/1/2025.
  • A Ribozyme Rescue Strategy for Dry Age-Related Macular Degeneration. John Sullivan (Principal Investigator). Veterans Administration BLRD Merit Award. $715,000. 10/1/2009-12/1/2024.
  • Pediatric network for the human cell atlas in the eye (Peds RFA). John Lillvis (Co-Investigator). Chan Zuckerberg Initiative. $400,712. 10/1/2021-9/1/2024.
  • Regulation of mRNA decay in retinal development and maintenance. Xiuqian Mu (Principal Investigator). National Eye Institute. $2,024,085. 4/1/2020-3/1/2024.
  • Immunotherapy for acute lung injury secondary to influenze. John Sullivan (Co-Investigator). National Heart Lung and Blood Institute. $1,747,088. 4/1/2020-3/1/2024.
  • ER stress and diabetic retinopathy. Sarah Zhang (Principal Investigator). NIH, NEI. 9/1/2010-2/1/2024.
  • ER stress and diabetic retinopathy. Joshua Jianxin Wang (Co-Investigator). 9/1/2010-2/1/2024.
  • Molecular Mechanisms of Severe Diabetic Retinopathy. Joshua Jianxin Wang (Co-Investigator), Sarah Zhang (Principal Investigator). NIH. 2/1/2020-1/1/2024.
  • Generation of a human cell neural retina atlas with single cell RNA Seq. Margaret DeAngelis (Co-Principal Investigator). Chan-Zuckerberg. $345,621. 10/1/2020-10/1/2023.
  • Epigenetic-guided studies of AMD pathology and iPSC-RPE transplantation therapy. Michael Farkas (Principal Investigator). Department of Veterans Affairs. 10/1/2019-9/1/2023.
  • Single nucleus chromatin accessibility and transcriptomic characterization of Age-related macular degeneration. Margaret DeAngelis (Principal Investigator). Genentech, Inc. $942,213. 6/1/2021-6/1/2023.
  • A Study of Estrogen and Body Mass Index in Fuchs’ Endothelial Corneal Dystrophy. Sangita Patel (Co-Investigator). NIH. $452,925. 7/1/2021-6/1/2023.
  • Investigating the Action and Physiological Role of Slc4a11 in the Cornea. Sangita Patel (Co-Investigator). NIH National Eye Institute. $1,972,804. 2/1/2018-1/1/2023.
  • NIH K08 (EY029007) Sex disparity and estradiol in Fuchs‘ endothelial corneal dystrophy. Sangita Patel (Principal Investigator). NIH. $854,900. 1/1/2018-1/1/2023.
  • Development of Enhanced Hammerhead Ribozymes (E-hhRzs) as Therapeutics for AMD and other Retinal Diseases. John Sullivan (Principal Investigator). JB McDonald Foundation, Evergreen CO Donald R. McJunkin, President. $15,000. 1/1/2022-12/1/2022.
  • A Ribozyme Rescue Strategy for Autosomal Dominant Retinitis Pigmentosa. John Sullivan (Principal Investigator). National Eye Institute. $975,000. 9/1/2003-9/1/2022.
  • Development and characterization of mouse models of RP59 DHDDS deficiency. Steven Fliesler (Co-Principal Investigator). National Eye Institute/NIH. $2,208,923. 9/1/2018-6/1/2022.